Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Foundation for Research in Genetics and Endocrinology, |
RCV001172401 | SCV001190357 | uncertain significance | Mucopolysaccharidosis, MPS-IV-A | criteria provided, single submitter | clinical testing | A homozygous splice site variation in intron 1 of the GALNS gene was detected. The observed variant c.121-7C>G has not been reported in the 1000 genomes, gnomAD and ExAC databases. The in silico prediction of the variant is damaging by MutationTaster2. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as a variant of unknown significance. | |
Labcorp Genetics |
RCV001172401 | SCV004284282 | likely pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2023-12-11 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 1 of the GALNS gene. It does not directly change the encoded amino acid sequence of the GALNS protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with Mucopolysaccharidosis type IVA (PMID: 35729508). ClinVar contains an entry for this variant (Variation ID: 916633). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |